Oral microbiome and oral and gastrointestinal cancer risk
- First Online:
- Cite this article as:
- Ahn, J., Chen, C.Y. & Hayes, R.B. Cancer Causes Control (2012) 23: 399. doi:10.1007/s10552-011-9892-7
- 1.6k Views
A growing body of evidence implicates human oral bacteria in the etiology of oral and gastrointestinal cancers. Epidemiological studies consistently report increased risks of these cancers in men and women with periodontal disease or tooth loss, conditions caused by oral bacteria. More than 700 bacterial species inhabit the oral cavity, including at least 11 bacterial phyla and 70 genera. Oral bacteria may activate alcohol and smoking-related carcinogens locally or act systemically, through chronic inflammation. High-throughput genetic-based assays now make it possible to comprehensively survey the human oral microbiome, the totality of bacteria in the oral cavity. Establishing the association of the oral microbiome with cancer risk may lead to significant advances in understanding of cancer etiology, potentially opening a new research paradigm for cancer prevention.
KeywordsHuman microbiomeOral and gastrointestinal cancerAssayEpidemiology
The NIH Human Microbiome Project, launched as a part of the NIH Roadmap for Medical Research, pointed to the need to accelerate our understanding of how our bodies and microorganisms interact to influence health and disease . It is hypothesized that the human microbiome is associated with human health and that dysbiosis can lead to a variety of diseases. Until recently, studies of the human microbiota have been based on bacterial culture, which we now know is limited and insensitive, because large numbers of nonculturables (up to 80%) cannot be studied in culture [2, 3]. The development of high-throughput genetic-based microbiome assays expedited studies to comprehensively examine the human microbiome, the totality of human microbiota, including nonculturable organisms. In the context of these developments, it is becoming possible to test the hypothesis that the oral microbiome and its imbalances are associated etiologically with cancers of the oral and gastrointestinal tracts.
Biological plausibility of the oral bacteria: oral and gastrointestinal cancer relationship
Epidemiological study of periodontal disease
It is well established that oral bacteria are critical to the development of periodontal disease and tooth loss , and these oral diseases have been related in a number of studies to the risk of oral and gastrointestinal cancers, with the most consistent increased risks noted in studies of oral and esophageal cancers, followed by evidence for pancreatic and gastric cancer (reviewed in [5, 6]); these relationships tend to persist after taking confounding factors into account—e.g., smoking, body mass index, and socioeconomic status [5–9]. The underlying mechanism for the associations between oral health status and these cancers is not completely understood, yet it is possible that these associations of cancers with oral disease may reflect a stronger underlying association of cancer with as yet unexamined oral microbiome profiles.
Local metabolism of carcinogens by oral microbiota
Systemic effects of oral microbiota
Associations of periodontal disease and tooth loss with cancers at distant sites, including stomach [19, 20] and pancreas cancer [8, 21, 22], suggest that systemic mechanisms may also be involved in oral microbiome-related carcinogenesis. It is becoming increasingly clear that periodontal disease is associated with systemic effects [23, 24], including consistent relationships with cardiovascular disease  and diabetes . Oral bacteria were found in atherosclerotic plaque, and importantly, successful treatment for periodontal disease, leads to reversal of systemic markers for these diseases, including improved endothelial function , decrease in inflammatory markers [26–28], and improved glycemic control in diabetics , providing strong evidence that periodontal disease is causally associated with these systemic effects. Although oral and gut microbiome community structures differ in the same individuals , certain oral bacteria are able to reach the GI tract (Ahn unpublished data). Alternatively, oral bacteria are sources of repeated transient systemic bacteremia after mastication, tooth-brushing, and dental procedures [31–35]. Furthermore, bacteria can provide a source of ligands for toll-like receptors (TLRs)  at target organ membrane receptors; TLRs are receptors on innate immune cells that bind structurally conserved molecules derived from microbes, collectively denoted pathogen-associated molecular patterns (PAMPs), and thereby potentially link inflammatory response and downstream cell signaling to a wide spectrum of human bacteria. Evidence is building that inflammation due to immunologic response to chronic exposure to bacteria and their toxins may play an important role in oral and gastrointestinal carcinogenesis [24, 37, 38].
Diversity at sampling sites
The oral cavity provides a diversity of environments for bacterial communities and consequently microbiome profiles differ for various intraoral surfaces. The microbiota of subgingival and supragingival plaque adherent to tooth structure tend to be similar, although anaerobes tend to predominate subgingivally. There is also variability in microbiota of the dorsal and lateral tongue and between epithelial covering of soft and bony tissues . Salivary microbial profiles tend to reflect the prevalence of bacterial pathogens in adherent oral biofilms and to be associated with risk for dental disease and pathogen transmission between individuals; also, a decrease in the salivary count of pathogens can serve as an indicator of therapeutic effectiveness in the treatment of oral disease . Thus, salivary microbial assessment may serve as a surrogate sample source for oral pathogens related to cancer risk.
Assays for the oral microbiome
Significant advances have been made in laboratory assay for genetic-based microbiome assessment, independent of bacterial culture . Current high-throughput approaches employ genetic sequences of 16S ribosomal RNA (or 16S rRNA), a component of the 30S subunit of prokaryotic ribosome. 16S rRNA is used in genetic microbiome assay because components of this sequence are highly conserved between different species of bacteria and archaea, while other type-specific components are highly variable. 16S rRNA structure is employed in the terminal restriction fragment length polymorphism (TRFLP) assay, in microarrays based on gene hybridization, and in 16S rRNA sequencing.
Terminal restriction fragment length polymorphism (TRFLP) is a molecular profiling of microbial communities based on the position of a restriction site closest to a labeled end of the amplified 16S rRNA gene . Following PCR of the16S rRNA gene, the mixture of amplicons is subjected to a restriction reaction. The mixture of fragments is separated using either capillary or polyacrylamide electrophoresis and the sizes of the different terminal fragments are determined by fluorescence detection. This method is a crude way to compare the molecular profiles of bacterial communities; however, it is not suitable for the identification of specific bacteria. A further limitation is that any two distinct sequences which share a terminal restriction site will result in one peak and will be indistinguishable.
16S rRNA gene pyrosequencing and the Human Oral Microbe Identification Microarray (HOMIM)  are two common high-throughput oral microbiome assays that provide rich microbiome assessment beyond the capacity of RFLPs. HOMIM uses specially designed probes to detect ~300 of the most prevalent oral bacterial species. Since this method is based on a preconstructed microarray, the community structure identified is limited to the specific hybridization probes selected for previously identified bacterial DNA sequences, but it has the advantages of lower cost and standardized data analysis. 16S rRNA gene pyrosequencing is a broad-based sequencing approach, using PCR primers to highly conserved regions for amplification of a segment of the 16S rRNA gene, followed by DNA pyrosequencing to identify unique sequence reads. Compared to traditional sequencing techniques like Sanger sequencing, pyrosequencing provides a larger number of reads and greater depth of coverage in a cost-efficient manner. Although pyrosequencing from 454 or Illumina provide shorter reads than Sanger sequencing, this next generation sequencing method is a significant advance to generate high-throughput, massively parallel processed sequencing, allowing the detection of greater microbial diversity due to the large number of reads and greater coverage depth.
We found that human oral microbiome community profiles assessed by 16S rRNA pyrosequencing and HOMIM were highly correlated at the phylum level and, for the more common taxa, at the genus level . Although the pyrosequencing method detects a greater number of rare genera, this differential may not be decisive in moderate-sized epidemiologic studies where power is limited to detect risks associated with relatively rare exposures. We consider both methods currently suitable for high-throughput epidemiologic investigations relating the oral microbiome to disease risk .
Strengths and limitations of human oral microbe identification microarray (HOMIM) assay, 16S rRNA gene pyrosequencing, and metagenomic approach
HOMIM: microarray-based 16AS rRNA hybridization
Pyrosequencing: partial 16S rRNA gene sequencing
Metagenomics: entire microbiome community gene sequencing
Focused detection of common known species
Broad detection range of taxa
Broad detection range of taxa
Custom array-based approach, covered by reference sequences
Detection of unclassified microbes
Possible to infer functional and phenotypic relationships for gene families
Quantification based on relative intensity score
Quantification based on sequence reads
Quantification based on sequence reads
Relatively low assay cost
Relatively high assay cost
Highest assay cost
Relatively less labor intensive
Relatively more labor intensive
Most labor/data intensive
Human oral microbiome community structure
Conclusion and future directions
High-throughput microbiome assay technology has opened the door for “microbiomic” epidemiology; initial efforts have provided testable hypotheses using these high-throughput microbiome assays, relating the oral microbiome to risk for oral cancer  and esophageal microbiome to premalignant Barrett’s esophagus . Yang et al.  examined whether esophagus microbiome is associated with esophagitis and Barrett’s esophagus in tissue samples from 34 subjects. They identified a “type I” microbiome dominated by the genus Streptococcus and concentrated in the normal esophagus and a “type II” microbiome containing a greater proportion of gram-negative anaerobes/microaerophiles and primarily correlated with esophagitis (OR = 15.4) and Barrett’s esophagus (OR = 16.5), suggesting the feasibility to classify microbiome associated with this premalignant disease. In a small case–control study of oral microbiome with oral cancer  (10 cases and 10 controls), oral squamous cell cancer/leukoplakia was associated with an apparent decrease in the relative abundance of streptococcus (22.3%) compared with nonsmoking (39.4%) and smoking controls (40.1%).
While initial steps are promising , multi-disciplinary collaborations in epidemiology, microbiology, genetics, immunology, and bioinformatics will be needed to broaden our understanding of the relationship of oral bacteria to cancer risk . Establishing the association of the oral microbiome with cancer may lead to significant advances in understanding of cancer etiology, potentially opening a new research paradigm for these diseases. The identified oral bacterial profiles may also serve as readily accessible, noninvasive biomarkers for the identification of high risk for cancer, complementing known risk factors for these diseases. If these relationships are confirmed as causal, findings may also lead to microbial prophylactic cancer prevention in clinical practice.
This work was supported by Grants R01 CA159036 and P30 CA016087 from National Cancer Institute.